Covid-19 (Temas de Saúde Pública)

[Preprint] Transmissão domiciliar da variante Ômicron do SARS-CoV-2 na Dinamarca.

28 Jan, 2022 | 16:22h

SARS-CoV-2 Omicron VOC Transmission in Danish Households – medRxiv

Comunicado de imprensa: Danish researchers investigate Omicron transmission in Danish households – Statens Serum Institut

 

Comentário no Twitter

Reminder that, despite its infectivity, Omicron's household attack rate is ~1-in-3 (less in fully vaxxed). People often assume that, if one person in household is infected, it's inevitable everybody'll get it. Ain't so; worth trying to isolate if feasible.https://t.co/OLcUtfH8Up

— Bob Wachter (@Bob_Wachter) January 23, 2022

 

---

Estudo laboratorial italiano mostra que a vacina Sputnik V supera a vacina de mRNA da Pfizer contra a variante Ômicron – produzindo níveis maiores de anticorpos.

28 Jan, 2022 | 16:21h

Italian Lab Study Finds Sputnik V Beat Pfizer’s mRNA Vaccine Against Omicron – Yielding Higher Antibody Levels – Health Policy Watch

---

Estudo randomizado | Reforço de vacinação heterólogo (Pfizer, J&J ou AstraZeneca) vs. homólogo em pessoas que receberam previamente 2 doses da vacina CoronaVac no Brasil.

28 Jan, 2022 | 15:47h

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study – The Lancet

Comentários:

Boosting immunity after CoronaVac – The Lancet

Covid-19: CoronaVac immunity is strongest after boosting with a different vaccine – The BMJ

Estudo relacionado: Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination – Nature Medicine

 

Comentário no Twitter

Heterologous boosting after 2 doses of #CoronaVac COVID-19 vaccine results in more robust immune responses than homologous boosting, study suggests. https://t.co/845JFnn3t7 pic.twitter.com/ibT3b5rs2K

— The Lancet (@TheLancet) January 23, 2022

 

---

Estudo de coorte | Entre sobreviventes de tratamento em UTI para COVID-19, 75% ainda relatam sintomas físicos, mentais e cognitivos depois de 1 ano.

28 Jan, 2022 | 15:45h

Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19 – JAMA

Comentários:

75% of COVID ICU survivors have physical symptoms 1 year on – CIDRAP

Majority of COVID-19 survivors experience health problems one-year post ICU admission – News Medical

---

Enquanto Pfizer e BioNTech iniciam um estudo clínico de vacina baseada na variante Ômicron, não se tem clareza quanto ao tempo para autorização.

28 Jan, 2022 | 15:41h

As Pfizer and BioNTech begin clinical trial of Omicron-based vaccine, timeline to authorization is unclear – STAT

Ver também:

Pfizer begins testing omicron-matched COVID shots in adults – Associated Press

Pfizer and BioNTech start trials of new Omicron-specific jab – BBC

Pfizer and BioNTech begin testing an omicron-specific COVID-19 vaccine – NPR

---

Opinião | Prevenção da transmissão do SARS-CoV-2 em ambientes de cuidados em saúde no contexto da variante Ômicron.

28 Jan, 2022 | 15:38h

Preventing SARS-CoV-2 Transmission in Health Care Settings in the Context of the Omicron Variant – JAMA

 

Comentário no Twitter

Our new piece in @JAMA_current

Transmission of #SARSCoV2 in healthcare settings is a serious concern

We outline three ways hospitals can better prepare for surges— mandating boosters, increasing frequency of testing, & upgrading to N95 maskshttps://t.co/2xRKdKPlhO pic.twitter.com/y0L4UzUNSo

— Abraar Karan (@AbraarKaran) January 24, 2022

 

---

Breve revisão ACP | Risco de reinfecção após contágio pelo SARS-CoV-2.

25 Jan, 2022 | 15:07h

Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection – Annals of Internal Medicine

 

Comentário no Twitter

Risk for Reinfection After #SARSCoV2: previous infection reduced risk for reinfection by 87% (95% CI, 84% to 90%). Protection remained above 80% for at least 7 months, but no study followed patients after the emergence of the Delta or #Omicron variant. https://t.co/eruEf1w8Vo

— Prof. Nick Talley (@Prof_NickTalley) January 25, 2022

 

---

OMS deixa de se opor aos reforços de vacina – recomenda a terceira dose da Pfizer para adultos e 2 doses de vacinas para crianças a partir de 5 anos de idade.

25 Jan, 2022 | 15:06h

WHO Drops Opposition to Boosters – Recommends Third Pfizer Jab for Adults & Two Vaccines for Children Ages 5 & Up – Health Policy Watch

Conteúdos relacionados:

WHO updated roadmap for prioritizing uses of COVID-19 vaccines.

WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids.

---

Um estudo de caso-controle mostrou risco aumentado de miocardite após vacinação contra COVID-19 com vacina mRNA em comparação com vacina de vírus inativado.

25 Jan, 2022 | 15:04h

Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case–Control Study – Annals of Internal Medicine

Comunicado de imprensa: BNT162b2 COVID-19 vaccine associated with increased risk of carditis – American College of Physicians

Conteúdos relacionados:

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

---

Avaliação inicial da gravidade clínica da variante Ômicron do SARS-CoV-2 na África do Sul.

25 Jan, 2022 | 15:02h

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study – The Lancet

Comentário: Omicron severity: milder but not mild – The Lancet

 

Comentário no Twitter

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in S. Africa, Lancet. Individuals with Omicron vs previous infections 80% lower odds of being admitted to hospital, 70% lower odds of severe disease than Deltahttps://t.co/528NWfKrDN

— Monica Gandhi MD, MPH (@MonicaGandhi9) January 23, 2022

 

---